Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) President Kyle Michael Wool purchased 8,500 shares of the business's stock in a transaction on Monday, April 8th. The stock was purchased at an average cost of $2.99 per share, with a total value of $25,415.00. Following the completion of the acquisition, the president now owns 22,750 shares in the company, valued at $68,022.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Kyle Michael Wool also recently made the following trade(s):
- On Thursday, April 4th, Kyle Michael Wool acquired 19,000 shares of Dominari stock. The shares were bought at an average cost of $2.87 per share, with a total value of $54,530.00.
Dominari Stock Performance
NASDAQ DOMH opened at $2.87 on Thursday. Dominari Holdings Inc. has a 52-week low of $1.76 and a 52-week high of $3.76. The company has a market capitalization of $17.02 million, a P/E ratio of -0.65 and a beta of 0.91. The company has a fifty day moving average of $2.27 and a 200-day moving average of $2.22.
Institutional Trading of Dominari
Hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in shares of Dominari during the 2nd quarter worth $52,000. State Street Corp bought a new stake in shares of Dominari during the 2nd quarter worth $58,000. Renaissance Technologies LLC bought a new stake in Dominari in the second quarter worth $109,000. Geode Capital Management LLC bought a new stake in Dominari in the second quarter worth $126,000. Finally, BlackRock Inc. bought a new stake in Dominari in the second quarter worth $219,000. 42.48% of the stock is owned by institutional investors.
About Dominari
(
Get Free Report)
4 Cryptos BETTER than Bitcoin
From True Market Insiders | Ad
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Click For My #1 FREE Crypto for 2024
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
